Cellular immunotherapies for cancer.

about

Disease-Associated Plasmacytoid Dendritic Cells.Antitumor activity of EGFR-specific CAR T cells against non-small-cell lung cancer cells in vitro and in mice.

P2860

Q43930865-6EF26834-8DE1-4378-9360-18D181B273A5 Q48507616-B8CC20DE-E8F8-40A3-AB5E-73706B6B4841

P2860

Cellular immunotherapies for cancer.

Item

http://www.wikidata.org/entity/Q39389608

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Cellular immunotherapies for cancer.

@en

Cellular immunotherapies for cancer.

@nl

type

Item

label

Cellular immunotherapies for cancer.

@en

Cellular immunotherapies for cancer.

@nl

prefLabel

Cellular immunotherapies for cancer.

@en

Cellular immunotherapies for cancer.

@nl

P1476

Cellular immunotherapies for cancer.

@en

P2093

Ignacio Melero

http://www.w3.org/2001/XMLSchema#string

Luna Minute

http://www.w3.org/2001/XMLSchema#string

Marcos Vasquez

http://www.w3.org/2001/XMLSchema#string

Sara Labiano

http://www.w3.org/2001/XMLSchema#string

P2860

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

Adoptive T-cell therapy for cancer: The era of engineered T cells

A major secretory defect of tumour-infiltrating T lymphocytes due to galectin impairing LFA-1-mediated synapse completion.

Nivolumab plus ipilimumab in advanced melanoma.

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Nivolumab in previously untreated melanoma without BRAF mutation

An initial and rapid step of lytic granule secretion precedes microtubule organizing center polarization at the cytotoxic T lymphocyte/target cell synapse.

Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens.

c-Myc regulates expression of NKG2D ligands ULBP1/2/3 in AML and modulates their susceptibility to NK-mediated lysis.

Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis.

P304

e1306619

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/2162402X.2017.1306619

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Alvaro Teijeira

Iñaki Etxeberria

Pedro Berraondo

Álvaro Sánchez-Arráez

P577

2017-05-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28638729

http://www.w3.org/2001/XMLSchema#string

P932

5467985

http://www.w3.org/2001/XMLSchema#string

Cellular immunotherapies for cancer.

about

P2860

P2860

Cellular immunotherapies for cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932